Isomorphic Labs, Alphabet’s AI drug-discovery company, announced a $5 billion Series C on Nov. 17, 2026—just months after its $2.1 billion Series B. The round was co-led by Greenoaks and Sequoia Capital, with participation from Andreessen Horowitz, Alphabet, and other existing investors.
The capital is intended to scale the company’s AI drug-design engine, IsoDDE; expand its biology models and research; and build the capabilities needed to move its first therapeutic programs toward clinical trials.
The central question is execution:
Isomorphic has attracted unprecedented funding, but the decisive test will be whether its AI-designed candidates prove safe and effective in people. The company has described preclinical progress, while detailed results remain limited in public reporting.
Sources:
AI drugmaker Isomorphic restocks with $5B fundraise
Three thoughts on $5B: What matters most about Isomorphic's historic raise
Demis Hassabis' AI company raises $5 billion, months after he left as Google DeepMind CEO
Isomorphic Labs announces Series C investment round
Isomorphic Labs breaks biotech VC fundraising record with $5B series C
Isomorphic Labs raises $5bn to advance drug pipeline
Isomorphic Labs raises $5B as it looks to take drug candidates to clinical trials | TechCrunch
AI drug developer Isomorphic raises $5 billion in Series C round
Finance Watch: Big AI Promises Captivate Venture Investors As Isomorphic Raises $5bn
Isomorphic Labs raises $5B series C months after $2.1B round
Isomorphic Labs just closed a $5 billion Series C today. ...
Sequoia, Greenoaks Lead Isomorphic Lab $5 Billion Funding Round
Summit's rejection, Isomorphic's record $5B raise, obesity and ...
Isomorphic Labs Announces $5 Billion Series C Funding
Alphabet's Isomorphic Labs raised $5 billion in Series C funding for AI drug design